Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
24.99
+0.97 (4.04%)
At close: Nov 24, 2025, 4:00 PM EST
24.95
-0.04 (-0.16%)
After-hours: Nov 24, 2025, 7:49 PM EST
Zymeworks Employees
As of December 31, 2024, Zymeworks had 286 total employees, including 280 full-time and 6 part-time employees. The number of employees increased by 8 or 2.88% compared to the previous year.
Employees
286
Change (1Y)
8
Growth (1Y)
2.88%
Revenue / Employee
$470,213
Profits / Employee
-$221,773
Market Cap
1.87B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 286 | 8 | 2.88% |
| Dec 31, 2023 | 278 | -16 | -5.44% |
| Dec 31, 2022 | 294 | -164 | -35.81% |
| Dec 31, 2021 | 458 | 103 | 29.01% |
| Dec 31, 2020 | 355 | 99 | 38.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZYME News
- 19 hours ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 3 days ago - Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA - Seeking Alpha
- 5 days ago - Zymeworks: A Lot Of Moving Parts - Seeking Alpha
- 6 days ago - Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 days ago - Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer - GlobeNewsWire
- 7 days ago - Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets - GlobeNewsWire
- 7 days ago - Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise - Seeking Alpha
- 7 days ago - Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity - Seeking Alpha